Bank of America’s XTL Biopharmaceuticals XTLB Stock Holding History

Bank of America’s Portfolio XTLB Stock Details XTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-250	Closed	-$2K	–	7359
2018 Q1	$2K	Buy	+250	New	+$2.05K	﹤0.01%	6912

Other funds holding XTLB

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America's XTLB Position: Q2 2018 in Review

Bank of America sold out of XTL Biopharmaceuticals (XTLB) in Q2 2018, closing a stake of 250 shares — an estimated $2K sold.

Bank of America first reported a position in XTLB in Q1 2018 and held it in 1 quarter. The position peaked at $2K in Q1 2018. 5 funds tracked by Wall St. Rank hold XTLB as of Q2 2018.

Bank of America reported no remaining XTL Biopharmaceuticals position as of Q2 2018 after selling out during the quarter.
Bank of America sold 250 XTL Biopharmaceuticals shares in Q2 2018, an estimated $2K.
Bank of America first reported a position in XTL Biopharmaceuticals in Q1 2018 and held it in 1 quarter.
Bank of America's XTL Biopharmaceuticals position peaked at $2K in Q1 2018.
5 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q2 2018.

Based on Bank of America's 13F filing for Q2 2018, filed 14 Aug 2018.